185 related articles for article (PubMed ID: 35950035)
1. Reducing prostate biopsies and magnetic resonance imaging with prostate cancer risk stratification.
Davik P; Remmers S; Elschot M; Roobol MJ; Bathen TF; Bertilsson H
BJUI Compass; 2022 Sep; 3(5):344-353. PubMed ID: 35950035
[TBL] [Abstract][Full Text] [Related]
2. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
3. A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators.
Patel HD; Koehne EL; Shea SM; Fang AM; Gerena M; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
BJU Int; 2023 Feb; 131(2):227-235. PubMed ID: 35733400
[TBL] [Abstract][Full Text] [Related]
4. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
5. A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy.
Kelly BD; Ptasznik G; Roberts MJ; Doan P; Stricker P; Thompson J; Buteau J; Chen K; Alghazo O; O'Brien JS; Hofman MS; Frydenberg M; Lawrentschuk N; Lundon D; Murphy DG; Emmett L; Moon D
Eur Urol Open Sci; 2023 Jul; 53():90-97. PubMed ID: 37441340
[TBL] [Abstract][Full Text] [Related]
6. Does Multiparametric Magnetic Resonance of Prostate Outperform Risk Calculators in Predicting Prostate Cancer in Biopsy Naïve Patients?
Falagario UG; Silecchia G; Bruno SM; Di Nauta M; Auciello M; Sanguedolce F; Milillo P; Macarini L; Selvaggio O; Carrieri G; Cormio L
Front Oncol; 2020; 10():603384. PubMed ID: 33489907
[TBL] [Abstract][Full Text] [Related]
7. Elucidating the need for prostate cancer risk calculators in conjunction with mpMRI in initial risk assessment before prostate biopsy at a tertiary prostate cancer center.
Krausewitz P; Büttner T; von Danwitz M; Weiten R; Cox A; Klümper N; Stein J; Luetkens J; Kristiansen G; Ritter M; Ellinger J
BMC Urol; 2024 Mar; 24(1):71. PubMed ID: 38532370
[TBL] [Abstract][Full Text] [Related]
8. Improving the Early Detection of Clinically Significant Prostate Cancer in Men in the Challenging Prostate Imaging-Reporting and Data System 3 Category.
Morote J; Campistol M; Triquell M; Celma A; Regis L; de Torres I; Semidey ME; Mast R; Santamaria A; Planas J; Trilla E
Eur Urol Open Sci; 2022 Mar; 37():38-44. PubMed ID: 35243388
[TBL] [Abstract][Full Text] [Related]
9. Clash of the calculators: External validation of prostate cancer risk calculators in men undergoing mpMRI and transperineal biopsy.
Wei G; Kelly BD; Timm B; Perera M; Lundon DJ; Jack G; Bolton DM
BJUI Compass; 2021 May; 2(3):194-201. PubMed ID: 35475133
[TBL] [Abstract][Full Text] [Related]
10. The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator.
Parekh S; Ratnani P; Falagario U; Lundon D; Kewlani D; Nasri J; Dovey Z; Stroumbakis D; Ranti D; Grauer R; Sobotka S; Pedraza A; Wagaskar V; Mistry L; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Martini A; Picker W; Haug E; Cormio L; Nordström T; Briganti A; Boström PJ; Carrieri G; Haines K; Gorin MA; Wiklund P; Menon M; Tewari A
Eur Urol Open Sci; 2022 Jul; 41():45-54. PubMed ID: 35813258
[TBL] [Abstract][Full Text] [Related]
11. Head-to-head Comparison of Conventional, and Image- and Biomarker-based Prostate Cancer Risk Calculators.
Mortezavi A; Palsdottir T; Eklund M; Chellappa V; Murugan SK; Saba K; Ankerst DP; Haug ES; Nordström T
Eur Urol Focus; 2021 May; 7(3):546-553. PubMed ID: 32451315
[TBL] [Abstract][Full Text] [Related]
12. External validation of novel magnetic resonance imaging-based models for prostate cancer prediction.
Püllen L; Radtke JP; Wiesenfarth M; Roobol MJ; Verbeek JFM; Wetter A; Guberina N; Pandey A; Hüttenbrink C; Tschirdewahn S; Pahernik S; Hadaschik BA; Distler FA
BJU Int; 2020 Mar; 125(3):407-416. PubMed ID: 31758738
[TBL] [Abstract][Full Text] [Related]
13. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
14. Predictors of clinically significant prostate cancer in biopsy-naïve and prior negative biopsy men with a negative prostate MRI: improving MRI-based screening with a novel risk calculator.
van Riel LAMJG; Jager A; Meijer D; Postema AW; Smit RS; Vis AN; de Reijke TM; Beerlage HP; Oddens JR
Ther Adv Urol; 2022; 14():17562872221088536. PubMed ID: 35356754
[TBL] [Abstract][Full Text] [Related]
15. Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome.
Pereira-Azevedo N; Verbeek JFM; Nieboer D; Bangma CH; Roobol MJ
Transl Androl Urol; 2018 Feb; 7(1):18-26. PubMed ID: 29594016
[TBL] [Abstract][Full Text] [Related]
16. External validation of two mpMRI-risk calculators predicting risk of prostate cancer before biopsy.
Pallauf M; Steinkohl F; Zimmermann G; Horetzky M; Rajwa P; Pradere B; Lindner AK; Pichler R; Kunit T; Shariat SF; Lusuardi L; Drerup M
World J Urol; 2022 Oct; 40(10):2451-2457. PubMed ID: 35941246
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI.
Campistol M; Morote J; Triquell M; Regis L; Celma A; de Torres I; Semidey ME; Mast R; Santamaría A; Planas J; Trilla E
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681685
[TBL] [Abstract][Full Text] [Related]
18. Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer.
Deniffel D; Healy GM; Dong X; Ghai S; Salinas-Miranda E; Fleshner N; Hamilton R; Kulkarni G; Toi A; van der Kwast T; Zlotta A; Finelli A; Perlis N; Haider MA
Radiology; 2021 Aug; 300(2):369-379. PubMed ID: 34032510
[TBL] [Abstract][Full Text] [Related]
19. Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data.
Remmers S; Kasivisvanathan V; Verbeek JFM; Moore CM; Roobol MJ;
Eur Urol Open Sci; 2022 Feb; 36():1-8. PubMed ID: 35098168
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer.
Morote J; Borque-Fernando Á; Triquell M; Campistol M; Servian P; Abascal JM; Planas J; Méndez O; Esteban LM; Trilla E
Eur Urol Open Sci; 2023 Jul; 53():46-54. PubMed ID: 37441350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
